Adegramotide

Adegramotide is an experimental drug intended for treatment of various hematologic malignancies and solid tumors, including glioblastoma multiforme. It is a peptide vaccine and has finished phase I clinical trials and phase II clinical trials.
As of, phase III clinical research has been cancelled due to low efficacy markers during interim review of study data for Ombipepimut-S Emulsion in combination with Bevacizumab.
The phase III trials for DSP-7888 with checkpoint inhibitors for platinum-resistant ovarian cancer, as of, is still continuing as planned.